These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 31048548)
1. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Cronise KE; Hernandez BG; Gustafson DL; Duval DL Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548 [TBL] [Abstract][Full Text] [Related]
2. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target. Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755 [TBL] [Abstract][Full Text] [Related]
4. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459 [TBL] [Abstract][Full Text] [Related]
5. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202 [TBL] [Abstract][Full Text] [Related]
7. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer. Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281 [TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors. Ming Z; Lim SY; Kefford RF; Rizos H Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489 [TBL] [Abstract][Full Text] [Related]
10. Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines. Sakai K; Maeda S; Saeki K; Nakagawa T; Murakami M; Endo Y; Yonezawa T; Kadosawa T; Mori T; Nishimura R; Matsuki N Vet Comp Oncol; 2018 Dec; 16(4):642-649. PubMed ID: 30246405 [TBL] [Abstract][Full Text] [Related]
11. Hedgehog signaling is activated in canine transitional cell carcinoma and contributes to cell proliferation and survival. Gustafson TL; Kitchell BE; Biller B Vet Comp Oncol; 2017 Mar; 15(1):174-183. PubMed ID: 25864514 [TBL] [Abstract][Full Text] [Related]
12. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related]
13. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. Carroll MJ; Parent CR; Page D; Kreeger PK BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130 [TBL] [Abstract][Full Text] [Related]
14. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
15. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
16. Establishment of a BRAF V595E-mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer. Kobayashi M; Onozawa M; Watanabe S; Nagashima T; Tamura K; Kubo Y; Ikeda A; Ochiai K; Michishita M; Bonkobara M; Kobayashi M; Hori T; Kawakami E Vet Comp Oncol; 2023 Jun; 21(2):221-230. PubMed ID: 36745053 [TBL] [Abstract][Full Text] [Related]
17. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953 [No Abstract] [Full Text] [Related]
18. Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition. Parker R; Clifton-Bligh R; Molloy MP Mol Cancer Ther; 2014 Jul; 13(7):1894-906. PubMed ID: 24825855 [TBL] [Abstract][Full Text] [Related]
19. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886 [TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma]. Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]